table – Page 5 – Communicable Diseases Research

Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies

Conference abstract

Published on 2021-02-082022-10-05
Journal: Blood [Category] 유전자 메커니즘,

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Conference abstract

Published on 2021-02-082022-10-05
Journal: Blood [Category] 임상,

[키워드] A p-value Analysis analyzed average center clinical clinical trial comparison continuous variable COVID-19 data entry database defined disease download Efficiency funding greater group groups hematology Imago include increase in Increased Incyte independent of interquartile range IQR leukemia logistic regression model median median time Multiple myeloma no significant difference observation organizations pandemic Patient per day performed productivity random intercept recorded reduction in remote monitoring Research research coordinator Satisfaction significantly more site initiation site monitoring solid tumor Sponsor statistically significant study period table the median the SARS-CoV-2 Total translate Trial were excluded
[DOI] 10.1182/blood-2020-139937 [Article Type] Conference abstract

Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial

코로나바이러스 감염증(COVID-19) 감염이 확인된 병원에 입원한 환자의 레닌-안지오텐신-알도스테론 시스템 차단 관리(The McGill RAAS-COVID-19): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Study Protocol

Published on 2021-02-052022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 48 hour 48 hours ACE inhibitor ACE2 Acute kidney injury Admission age aldosterone All participants Amendment Analysis Anticoagulants approach assigned baseline Biomarker Biomarkers blinded Blinding blockade blood pressure BNP C-reactive protein C-reactive protein (CRP calculated calibrated cardiovascular disease change Clinical improvement clinical trials collected comparator component Consent coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 infection COVID-19 patient creatinine creatinine) CRP database death diagnosis of COVID-19 died discharge dissemination domains doubling Effect EGFR Ejection fraction element eligible Endpoint enrolment Estimated Ethnicity evaluate event exclusion criteria feasibility Follow-up followed by General Hospital greater groups Health Health Organization heart failure high blood pressure highest hospital ICU ICU admission immunopathology include Inclusion inclusion and exclusion criteria increase increase in Increases indicate Infection inhibitor inhibitors initial initiated intervention arm intravenous invasive ventilation list Lower lowest lymphocyte Lymphocyte count lymphocyte counts mathematical mathematical model McGill University mean rank mechanical ventilation medical history medication medications meet Montreal Mortality number objective Older open open label Ordinal Scale outcome outcomes participant Participants past medical history Patient patient cohort PCR performed Prevent primary end point primary endpoint Protein protocol provided RAAS RAAS inhibitor random number generator randomised randomised controlled trial randomization Randomized Randomized controlled trial recruitment reduced Registration Renin required Sample Sample size SARS- CoV2 secondary secondary endpoint sensitivity sensitivity analysis serum creatinine Sex short term stability statistical power calculations status stroke study participant Study protocol subsequent supplementary material System table team the patient the primary endpoint therapy transfer transferred Treatment Trial troponin Version Victoria ward website were excluded WHO withdrawn World Health Organization
[DOI] 10.1186/s13063-021-05080-4 PMC 바로가기 [Article Type] Study Protocol

Creation and maintenance of a table for assessment of evolving evidence for COVID-19-related treatments

COVID-19 관련 치료에 대한 진화하는 증거 평가를 위한 테이블 생성 및 유지

Review

Published on 2021-01-052022-09-11
Journal: American journal of health-system pharmacy : AJHP [Category] 임상, 치료제,

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

Psychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medications

Review Article

Published on 2021-01-012022-10-30
Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] COVID-19,

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial

COVID-19(IVERCOR-COVID19) 환자의 입원을 방지하기 위한 Ivermectin: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Randomized Controlled Trial

Published on 2020-11-242022-08-13
Journal: Trials [Category] SARS, 임상, 치료기술,

[키워드] 1:1 acute infectious disease addition adherence administration Admission adverse event adverse events age allergy analyzed Anthropometric data antiviral drug antiviral drugs Arm ARMS assessment barrier basal blinded Breastfeeding breastfeeding women Cardiology Care care providers carried cause Chain Reaction childbearing age Chloroquine cirrhosis component components Concomitant Concomitant medication Confirmed connection contraceptive method contraceptives Control control group control groups coordination Corriente COVID-19 COVID-19 patient population criteria current Day death demographic demographic data Diagnosis diagnosis of COVID-19 dialysis discharged dissemination dose double-blind drug Efficacy Efficacy and safety elapsed element EOS Equal example exclusion criteria Final final visit first dose Follow-up greater heart rate Hospitalization hospitalizations Hydroxychloroquine incidence include Inclusion inclusion criteria inclusion/exclusion criteria Informed consent Intervention Invasive mechanical ventilation investigator investigators Ivermectin Ivermectin safety Laboratory less liver Liver cirrhosis Liver disease mal-absorptive syndrome medical history medication menstrual menstrual cycles Mortality negative Negative PCR number objective outcome outcome assessor outcome assessors over oxygen oxygen saturation parallel group participant Participants Participation Patient patients with COVID-19 PCR PCR swab Placebo placebo-controlled study polymerase chain polymerase chain reaction Polymerase chain reaction test postmenopausal pregnant Presence Prevent Primary outcome protocol Public public health randomization Randomized Randomized controlled trial randomly permuted blocks receive recommendation recorded recruitment reducing renal replacement therapy replacement therapy reproductive required Research Sample size SARS-CoV2 secondary severe liver disease single-center standard treatment standard treatment alone Study protocol supplementary material surgical Swab table Tablet temperature the patient Total Treatment Trial Trial registration use of hydroxychloroquine Version Viral viral pathology Vital vital signs vital status web system website weight woman women
[DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial

A Risk Prediction Model for Evaluating the Disease Progression of COVID-19 Pneumonia

Medicine

Published on 2020-11-052022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] acute respiratory syndrome age Algorithm Analysis caused China Cohort cohorts Comorbidities coronavirus coronavirus disease COVID 19 COVID-19 CREA diabetes Disease progression enrolled Epidemic evaluate Evaluating Factor Fever help hospital hypertension identify Infection Laboratory LDH Logistic Logistic regression men Meta-analysis Model neutrophil count Patient Pneumonia prediction progression risk risk factor Risk prediction model SARS-CoV2 Severe COVID-19 pneumonia shown significantly sSARS—CoV-2 table the disease the median validation cohort validation cohorts was performed with COVID-19 women Wuhan
[DOI] 10.3389/fmed.2020.556886 PMC 바로가기 [Article Type] Medicine

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Conference abstract

Published on 2020-11-042022-10-05
Journal: Blood [Category] 유전자 메커니즘,

[키워드] Absolute lymphocyte count active cancer acute respiratory syndrome age ALC Allogeneic autologous B-cell lymphoma board Cancer therapy cardiac disease Care Cell center Cohort cohort of patient collected Comorbidities Complication conditions conducted coronavirus cough COVID-19 COVID-19 diagnosis COVID-19 in patient COVID-19 infection database defined demographic characteristics described Diagnosis diagnosis of COVID-19 died download electronic medical records expected experience Fever for inclusion funding health system Hematologic malignancy higher risk HM patient Hospital admission ICU immune dysfunction impacted include Infection Innate intubation Jazz Kiowa laboratory data lymphopenia majority median mortality rate Multiple myeloma Nasopharyngeal swab network Older age outcome pandemic Patient patients patients with HM positive result presenting symptom presenting symptoms Prevalence promote rates of infection real-time RT-PCR required Retrospective study risk factor robust SARS-CoV-2 SCT Seattle severe COVID-19 Shortness of breath shown Smokers social distancing specimen subsequent supportive care symptomatic table therapy treated Treatment Two patient underlying disease with COVID-19
[DOI] 10.1182/blood-2020-140719 [Article Type] Conference abstract

Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational Study

Conference abstract

Published on 2020-11-042022-10-05
Journal: Blood [Category] 바이오마커,

[키워드] Activation acute respiratory distress acute respiratory syndrome Algorithm Antithrombotic AP-HP ARDS Biomarker Blood coagulation calculated cause cellular change characterized clinically clotting factor Cluster Coagulation cohort study complications consecutive patient Control control group controls coronavirus coronavirus disease COVID-19 D-dimer decrease disease download effect of treatment endothelial Endothelial cell Endothelial dysfunction enrolled evaluate evaluated excessive inflammation expressing fibrinogen FVIII healthy individual Heparanase Hospitalized hypercoagulability ICU ICU admission ICU patient IL-6 IL-6 level increase indicate indicated inflammatory reaction Inhaled inhibitor intensive care unit intrinsic life-threatening LMWH management mandatory Microparticle moderate modify molecular weight monomer MRI Multisystem organ failure outcome Paris pathway Patient patients patients hospitalized patients with COVID-19 peak platelet activation Pneumonia Prospective Prospective Study Protein protein S ranged Ratio Respiratory failure Result SARS-CoV-2 SARS-COV-2 infection severe COVID-19 shown significant decrease significantly STABLE syndrome table TFPI the mean the patient thrombin Thromboprophylaxis university von Willebrand factor were assessed with COVID-19
[DOI] 10.1182/blood-2020-140275 [Article Type] Conference abstract